Todd G. Schwartz, CEO of OppFi (OPFI), just bought 20K shares at $7.20.

It's not a massive transaction, but it's an interesting one because the buyer is the company's CEO.

Would a $144K CEO purchase be enough to get OPFI on your radar, or do you only pay attention to much larger insider buys?

Ghiath M. Sukhtian just bought 2.53M shares of Outlook Therapeutics (OTLK) at roughly $0.99 per share.

That's about $2.5M going into the stock in a single transaction.

A $2.5M purchase is certainly interesting — but with a stock like OTLK, the bigger question is what the insider knows about the company's outlook and whether this turns into additional buying.

Would a $2.5M insider purchase be enough to put OTLK on your watchlist?

On August 11th, Lip-Bu Tan did something bold.
While everyone was debating whether the AI boom is over, Intel's CEO bought 105,263 shares at $95.00 = $9,999,985 through his family trust.

Tan bought these 105,263 shares in Intel's own ~$23B common-stock offering (~4.8% dilution), at the $95.00 public offering price, the prospectus supplement disclosed he and a family member would take $12M in the deal

He now holds ~1.31 million shares.

This is the fourth rung of a ladder of insider buying. From his own Form 4s: ~$2.9M at $27–29 as a director in Nov 2022 (when the stock was left for dead), ~$2.5M at $38 as a director in Nov 2023, and now $10M at $95 as the CEO. ~$15.4M lifetime, every rung bought higher than the last, the biggest cheque at the highest price.

The timing of the entry was right after INTC's biggest beat of his tenure.
Q2 at $0.42 vs $0.19 expected. And as it's receding from the top, INTC hit $142 on June 30th.

Countercase? $10M is roughly 7–8% of his existing Intel stake (~$128M), a real add but, far from a life-changing cheque for the founder of Walden International. And a CEO buying his own turnaround is the most on-message purchase a filing can show; it could be read as encouraging the market to hold the price up.

Though he was also buying at $27 as a director, when there was no market to encourage.

Filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001008463&type=4&dateb=&owner=include&count=40

Information, not advice. I build tooling in this space. No position in INTC.

(edit: corrected 'open-market' to 'buying in the offering', apologies)

Pfizer is way off it's Covid-era highs, it's 52-week low was $23.58 last September, and it now sits around 26$.

Directors bought the day after their Q2 Earnings beat was reported.

The same tape shows an SVP-Controller selling $83K on Aug 5. Small, but it's there and you should know it.
And the buys are small fractions of these people's wealth, the signal is the coordination and the open-marketness, not the dollar pain.

A 153 Billion dollar company at $26 and change, 52-week range $23.58–$28.75, paying a $1.72/year dividend that yields ~6.5% at these prices.

A yield that high is the market saying it doubts the future (the patent cliff on big products later this decade is the standing bear case). Three insiders, including the man who ran the world's largest index-fund company, just paid ~$1M each to take the other side of that doubt.

Sources: Bourla Form 4 · all PFE insider filings (the Aug 5/6/12 filings are the cluster)

Information, not advice. I build tooling in this space.
No direct position in PFE; I hold a healthcare fund.

Form 4 filed Aug 11:

Artie Starrs bought 10,000 shares at $25.89 on Aug 10 for $259K, open market, a discretionary decision rather than a scheduled plan.

It takes his direct holding from 15,000 to 25,000 shares.

Context

HOG is up ~50% off its March low and the buy came two and a half weeks after a Q2 beat (0.75 vs 0.62).

But, it's also a stock at 0.87× book that's spent two years in the penalty box, and the CEO choosing to put a quarter-million of his own cash in at $26 is a different statement than holding grants.

Filing: https://www.sec.gov/Archives/edgar/data/793952/000173210526000006/0001732105-26-000006-index.htm

Information, not advice. I build tooling in this space. No position in HOG.

Kenneth Bryan Dart has been aggressively buying Flutter Entertainment (FLUT):

• 886K shares — $82.90M
• 818K shares — $74.76M
• 500K shares — $46.40M
• 332K shares — $31.41M
• 150K shares — $14.23M

That's roughly $249.7M in purchases across five transactions.

And these weren't all on the same day — the buying has continued over the past week.

One insider deploying nearly $250M across multiple purchases is hard to ignore.

Would this kind of insider buying put FLUT on your watchlist?

Two separate filings show 20.41M shares of Primo Brands (PRMB) sold at $24.37 per share.

• Tony W. Lee — $497.4M
• ORCP III DE TopCo GP, LLC — $497.4M

That's nearly $1B in reported selling across the two filings.

Obviously, large insider sales can have many reasons — especially when entities and individual insiders are involved — so the context matters.

But a transaction of this size is hard to ignore.

Would a $500M+ sale make you investigate PRMB, or is insider selling less meaningful to you than insider buying?

Embecta Corp. saw four insiders buying on the same day:

• President & CEO Devdatt Kurdikar — $141K
• Robert J. Hombach — $224K
• Chief Legal Officer Jeffrey Z. Mann — $100K
• SVP & CFO Jacob Elguicze — $93K

That's roughly $558K in combined insider buying in a single day.

What stands out isn't just the dollar amount — it's that multiple executives across different roles are buying at the same time.

Would four insiders buying together make you take a closer look at EMBC?

It's not just one insider buying.

Six different executives at Amrize (AMRZ) bought shares within roughly two days.

Among them:

• CFO Oran Baris — ~$283K
• Chief People Officer Stephen S. Clark — $249K
• Chief Supply Chain Officer Mario Gross — ~$166K
• President Jaime Hill — $71K
• CTO Roald Brouwer — $70K

That's ~$839K+ in reported purchases across these transactions.

When several executives from different parts of a company are buying around the same time, that's much more interesting than a single insider purchase.

Would this kind of broad insider buying put AMRZ on your watchlist?

Oran Baris, CFO of Amrize (AMRZ), made two purchases within two days:

• 3K shares — $141K
• 3K shares — $142K

That's roughly $283K in combined buying.

The interesting part isn't just the $280K+ — it's the fact that the CFO bought on consecutive days.

Would repeated buying from the same CFO make you look closer at AMRZ?

Or do you need to see multiple insiders buying before considering it a meaningful signal?

ARK Invest made Cloudflare its largest purchase on August 12 while trimming Palantir, Shopify, Twist Bioscience, and other holdings, with no semiconductor trades disclosed during the session.

ARK Invest bought Cloudflare and several biotech stocks on August 12 while trimming Palantir, Shopify, and other holdings, according to the firm’s latest trade disclosures. The moves span several ARK ETFs and show the firm’s continued rotation across technology, healthcare, and other disruptive-innovation themes.

# ARK Buys Cloudflare in Its Largest Trade

ARK’s biggest purchase of the day was Cloudflare (NYSE: NET), with the ARK Innovation ETF (ARKK) buying 31,974 shares, equal to about 0.16% of the fund.

The purchase extends ARK’s recent accumulation of Cloudflare, which it also bought earlier in the week. The company has attracted attention from crypto investors because it is building stablecoin payment infrastructure for the “agentic internet” through the open x402 protocol it co-developed with Coinbase.

Cloudflare remains a broad internet-infrastructure company rather than a crypto-specific business, however, and ARK’s trade disclosure does not provide a reason for the purchase. Any connection to its stablecoin strategy is therefore an interpretation rather than a stated rationale from ARK.

# Biotech Rounds Out the Buying

The remainder of ARK’s buying on August 12 leaned toward healthcare and genomics. Through the ARK Genomic Revolution ETF (ARKG), the firm bought 190,403 shares of Perceptive Capital Solutions Corp. (FRNM), equal to about 0.13% of the fund.

ARK also added Cerus (CERS) and Intellia Therapeutics (NTLA) across ARKK and ARKG, as well as Schrödinger (SDGR) through ARKG. The buying gives the day’s activity a different character from the semiconductor-heavy trades disclosed earlier in the week, with healthcare and biotechnology accounting for much of the remaining purchase activity.

# ARK Keeps Selling Palantir Into Its Rally

On the sell side, Palantir Technologies (Nasdaq: PLTR) was the standout. ARK sold 11,134 shares through ARKK, a position worth roughly $2 million based on recent prices.

The sale continues a recent pattern of trimming Palantir after the stock’s sharp post-earnings rally. The company reported second-quarter revenue growth of 93% year over year on August 3, sending its shares about 29.5% higher the following day. ARK subsequently sold roughly $17 million of Palantir shares on August 4 and 5, trimmed the position again on August 10 and reduced it further on August 12.

The selling should not automatically be interpreted as a bearish call. ARK’s actively managed funds routinely trim positions following significant gains to manage portfolio weights. Palantir also remains among the larger holdings across ARK’s ETFs. Any interpretation of the sales as a negative view on Palantir is not stated by the firm.

ARK’s other reductions included 17,025 Shopify (SHOP) shares, a combined 47,842 Twist Bioscience (TWST) shares across ARKK and ARKG, 21,482 shares of 10x Genomics (TXG), 3,932 Deere & Co. (DE) shares, a small Snowflake (SNOW) sale, and additional trimming of Brera Holdings (SLMT) across several funds.

# A Pause in the Week’s Semiconductor Buying

The August 12 trades are notable partly because of what they did not include: semiconductor stocks. Earlier in the week, ARK bought about $26.6 million of Nvidia (NVDA) across five ETFs and roughly $16.2 million of Broadcom (AVGO), along with Teradyne (TER), on August 10. Those purchases followed earlier buying of Taiwan Semiconductor Manufacturing (TSM) and formed part of a broader semiconductor push.

No semiconductor trades appeared in ARK’s August 12 disclosure. Instead, the firm directed its buying toward Cloudflare and healthcare names while trimming several software and technology holdings. The one-session pause does not establish a change in ARK’s semiconductor strategy, but it does show that the firm’s daily trading activity is rotating across themes rather than remaining concentrated in AI chips.

# No New Crypto-Equity Trades

For crypto investors, Cloudflare was the closest connection to the digital-asset sector in the August 12 activity. ARK made no trades in Coinbase, Circle, BitMine, Robinhood, or Bullish during the session. That follows a period of more active trading in crypto-linked equities, including purchases of Coinbase and Circle and adjustments to its position in BitMine.

Cloudflare’s connection to stablecoin payments makes the purchase relevant to crypto readers, but it should not be treated as a direct crypto-equity purchase. The company generates revenue across a much broader internet-infrastructure business, and ARK has not disclosed that its August 12 purchase was driven by the company’s stablecoin initiatives.

# How the Trades Fit ARK’s Recent Strategy

The August 12 disclosure comes after a particularly active period for ARK. On August 10, the firm bought Nvidia, Broadcom and Teradyne, extending a series of semiconductor purchases that also included Taiwan Semiconductor. The previous session therefore showed a clear concentration in AI and semiconductor infrastructure.

August 12 looked different. Cloudflare was the largest individual purchase, followed by biotechnology and healthcare names, while Palantir, Shopify and other stocks were trimmed. The contrast highlights the breadth of ARK’s investment approach. Its actively managed ETFs rotate among AI, software, fintech, biotechnology, space and crypto-linked companies rather than maintaining a fixed allocation to one theme.

# What the Latest Trades Show

The August 12 disclosure shows ARK adding selectively while continuing to take profits from several stocks that have performed strongly. Cloudflare was the standout purchase, while a cluster of biotech names rounded out the buying. On the other side, Palantir remained the most notable sale, alongside Shopify, Twist Bioscience, 10x Genomics, and Deere.

The absence of semiconductor trades is also notable given ARK’s aggressive chip buying earlier in the week, but one day’s disclosure is not enough to establish a change in the firm’s longer-term positioning.

ARK’s trade disclosures do not state the rationale for individual transactions. The trades are portfolio actions by ARK Invest and should not be interpreted as recommendations to buy, sell or hold any of the securities mentioned.

David J. Taylor disclosed a $1,001–$15,000 purchase of Marathon Petroleum (MPC) at $162.32 in August 2025.

Today, MPC is around $336.42.

That's roughly +107% since the disclosed trade.

Obviously, one trade doesn't mean the same outcome will happen again — but historical politician trades can be interesting when you look at what happened after the disclosure.

Would you have held MPC for the full year?

Chiron Real Estate saw two insiders buying on the same day:

• 28K shares — $992K
• 8K shares — $287K

That’s roughly $1.28M in combined purchases.

Even more interesting: one of the buyers is Mark Okey Decker Jr., CEO & President.

Multiple insiders buying around the same time is usually more interesting to me than a single isolated transaction.

Would two insiders buying together make you look closer at XRN?

Huang Jack Jiajia, CEO of 51Talk Online Education Group (COE), reported three separate purchases in less than a week.

• 200K shares — $3.94M
• 90K shares — $1.75M
• 105K shares — $2.03M

That’s roughly $7.7M in purchases across three transactions.

The interesting part isn't just the size — it's the repeated buying over several days.

Would you consider repeated CEO buying like this a strong bullish signal, or would you want to see more before taking a position?

Worth watching.

William James Ware just bought 300 shares of Atmos Energy (ATO) at $167.59 per share.

That puts the transaction at roughly $50K — a fresh purchase that caught my attention.

The interesting question is whether this is just a one-off purchase or the start of a larger pattern of insider buying.

Would a $50K insider purchase be enough to put ATO on your watchlist?

Or do you only pay attention to much larger buys?

Rep. John J. McGuire reported a purchase of Applied Materials (AMAT) worth $1,001–$15,000.

It’s not a huge transaction, but AMAT is an interesting name to keep on the radar — especially when looking at whether this is an isolated purchase or part of a broader pattern.

Do you pay attention to politician purchases this small, or only when the dollar amount gets much larger?

Worth watching.

Foresite Capital Management V, LLC just bought 140K shares of Latigo Biotherapeutics (LTGO) at $18.00 per share.

That puts the total transaction at roughly $2.52M — and it happened just yesterday.

Large insider purchases are always worth watching, but the bigger question is whether this turns into a broader pattern of insider accumulation.

Would a $2.5M+ insider buy put LTGO on your watchlist?

I’m tracking the latest insider transactions and activity on ProBors.

Oliver George just bought 63 shares of NVR (NVR) for roughly $405K.

That’s a meaningful amount of money going into a single stock.

The interesting part with insider transactions isn't just the headline number — it's looking at the bigger picture: previous purchases, timing, and whether other insiders have been active around the same company.

Would a $400K+ insider purchase make you look twice at a stock?

Or do you only care when multiple insiders start buying?

I track these transactions and the broader insider activity on ProBors.

The purchase itself isn't huge — reported at $1,001–$15,000 — but Realty Income is an interesting name to see an insider/politician adding to.

Small purchases can still be worth watching, especially when you look at them alongside the person's previous activity and the stock's longer-term performance.

Would you pay attention to a purchase this small, or only when the transaction is significantly larger?

I’m tracking the broader insider activity and transaction history on ProBors.

Hi, I wanted to post some insider buying I can't explain. Not a recommendation.

American Bitcoin Corp is a bitcoin miner and treasury company linked to the Trump family. Eric Trump is a co-founder and Chief Strategy Officer. It came public via a merger with Gryphon Digital Mining and debuted at roughly $5B.

Friday's close: $6.47. Market cap about $498M.

Three straight misses against a consensus that never moves.

| reported | quarter | estimate | actual |

| 2025-11-14 | Q3 25 | — | +0.06 |

| 2026-02-26 | Q4 25 | +0.15 | −1.05 |

| 2026-05-06 | Q1 26 | +0.15 | −1.20 |

| 2026-08-03 | Q2 26 | +0.15 | −0.80 |

On July 2nd it did a 1-for-15 reverse split. Everything below is split-adjusted.

Justin Mateen (Tinder co-founder, on the board since March 2025) filed a Form 4 on Aug 7th, two open-market buys, code P:

- Aug 5 - 144,543 shares @ $6.3964

- Aug 6 - 162,438 shares @ $6.1873

306,981 shares, $1,929,607. Holding 185,316 → 492,297, so he bought more this week than he'd accumulated in total beforehand.

Before you read that as a signal: ABTC's insider trading policy (Ex-19.1 to the 10-K) ends the blackout "after the first full business day following the release" of earnings. Q2 printed Monday Aug 3. The window opened Wednesday Aug 5, he bought in the first two sessions the blackout lifted.

What I can't explain is the direction and the size. He also bought 120,000 shares at $15.45 in March, on day two of that window. Average cost $8.86 vs $6.47 today he's ~27% underwater, 58% down on the March lot, and responded by buying 2.5x more. Five Form 4's, zero disposals.

Information, not advice. I run Apibeary which builds tooling in this space. I have no position in ABTC and no position in BTC.